Exhibit 99.1 Cellebrite Announces Third-Quarter 2024 Results Third-quarter 2024 revenue of $106.9 million exceeds $100 million quarterly revenue milestone for the first time in Company history Third-quarter 2024 revenue increased 27% year-over-year primarily due to 27% growth in subscription revenue ARR of $370.8 million, up 26% year-over-year Third-quarter 2024 adjusted EBITDA of $31.3 million, 29.3% adjusted EBITDA margin Company increases 2024 outlook for revenue and adjusted EBITDA, and raises the low e ...

Cellebrite DI Ltd. (CLBT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its third-quarter 2024 financial results before market open on Wednesday, November 6, 2024. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the third quarter of 2024 and discuss its 2024 outlook. Releva ...

Have you been paying attention to shares of Cellebrite DI Ltd. (CLBT) ? Shares have been on the move with the stock up 7.7% over the past month. The stock hit a new 52-week high of $18 in the previous session. Cellebrite DI Ltd. has gained 104.2% since the start of the year compared to the 13.2% move for the Zacks Business Services sector and the 28.8% return for the Zacks Technology Services industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as i ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today the patent for Remote Mobile Collection, which equips corporate investigators with immediate, targeted remote data collection – saving them time and money. In today's hybrid work environment, this newly patented technology – available in Cellebrite's SaaS platforms Endpoint Mobile Now and Endpo ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT) ("Cellebrite," the "Company" or "we"), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today the results of the completed redemption (the "Redemption") of its Warrants (as defined below) to purchase ordinary shares of the Company (the "Ordinary Shares"). On August 15, 2024, the Company announced that it will redeem all of its Warrants that ...

Pathfinder's capabilities are now available via the cloud, giving law enforcement new deployment options to accelerate justice TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today Pathfinder in the Cloud with Amazon Web Services (AWS) (Nasdaq: AMZN), allowing customers to access Cellebrite's industry-leading investigative analytics solution, Path ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT) ("Cellebrite," the "Company" or "we"), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today the "Redemption Fair Market Value" in connection with its previously announced redemption of its warrants (the "Warrants") to purchase ordinary shares of the Company (the "Ordinary Shares"). On August 15, 2024, the Company announced that it will rede ...

AzmanL/E+ via Getty Images Summary A brief update from my last coverage (11th July): I gave Cellebrite (NASDAQ:CLBT) a buy rating as the business's strong competitive advantage, mission-critical function, and great execution convinced me that it can continue to grow at 20%. In this update, I am revising my rating from buy to hold because valuation has caught up, which makes the upside much less attractive today despite a better fundamental outlook. 2Q24 results perform even better than I expected. In the la ...

Cellebrite DI Ltd. (CLBT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock ...